FDA explains why it won't pull Jazz's accelerated approval despite a failed confirmatory trial

When does a failed confirmatory trial evaluating overall survival not amount to a request from FDA to pull an accelerated approval for a cancer drug? That’s the situation right now for Jazz Pharmaceuticals’ second-line treatment for adults with metastatic small cell lung cancer, which it spent $1 billion to acquire in 2019.